Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice.
Selma AtalayJuul M P A van den ReekHans M M GroenewoudPeter Cornelis Maria van de KerkhofWietske KievitElke M G J de JongPublished in: The Journal of dermatological treatment (2021)
The proposed dose reduction strategy is effective for a significant part of patients and remains safe up to 2 years of follow-up.